The Comparison of Percent Free PSA with total PSA in the diagnosis of Prostate Cancer

Journal of the Pakistan Medical Association

Volumn 53, Issue 6, 2003, Pages 233-236

  Rafi, T ^a   Sattar, A ^a   Asif, N ^a   Dawood, M M ^a   Aamir, M ^a   Rehman, Z ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONFIDENCE INTERVAL; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NODULAR HYPERPLASIA; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATECTOMY; SENSITIVITY ANALYSIS; SERUM; TIME SERIES ANALYSIS;

EID: 39049159719     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Brawer MK. Prostate specific antigen: Current status. CA Cancer J Clin 1999; 49: 264-81.
2. Henricks WH, England BG, Giacherio DA, et al. Serum percent free PSA does not predict extraprostatic spread of prostate cancer. Am J Clin Pathol 1998; 5: 533-9.
3. France MW, Seneviratne CJ. Screening for prostate cancer: case finding is not the problem. Ann Clin Biochem 1997; 34: 333-8.
4. Armbuster DA. Prostate specific antigen: biochemistry, analytical methods and clinical application. Clin Chem 1993; 39: 181-95.
5. Bunting PS. A guide to the interpretation of serum prostate specific antigen levels. Clin Biochem 1995; 28: 221-41.
6. Stamey TA, Yang N, Hay AR, et al. Prostate specific antigen as a serum marker for adenocarcinoma of prostate. N Eng J Med 1987; 317: 909-16.
7. Lilja H, Christensson A, Dahlen U, et al. Prostate specific antigen in serum occurs predominantly in complexes with a 1 antichymotrypsin. Clin Chem 1991; 37: 1618-25.
8. Petter5sson K, Piironen T, Seppala M, et al. Free and complexed prostate specific antigen (PSA): in vitro stability, epitope map and development of immunofluorometric assays for specific sensitive detection of free PSA and PSA α-1 antichymotrypsin complex. Clin Chem 1995;41:1480-6.
9. Oesterling JE, Jacobson SJ, Klee GG, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154:1090-5.
10. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update. J Urol 1994;152:1358-68.
11. Duffy MJ. PSA as a marker for prostate cancer: a critical review. Ann Clin Biochem 1996;33:511-19.
12. Schreiber WE. Free prostate specific antigen: does it measure up? editorial. Am J Clin Pathol 1998;5:511-13.
13. Dew T, Coker C, Saadeh F, Mulvin D, Coptcoat MJ, Sherwood RA. Influence of investigative and operative procedures on serum prostate specific antigen concentration. Ann Clin Biochem 1999; 36: 340-6.
14. Woodrum DL, Brawer MK, Partin AW, et al. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998; 159: 5-12.
15. Christenssen A, Bjork T, Nilsson O, et al. Serum prostate specific antigen complexed to α1antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5.
16. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum PSA to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214-20.
17. Vashi AR, Wojno KJ, Henrick BA, et al. Determination of reflex range and appropriate cut points for percent free prostate specific antigen in 413 men refered for prostatic evaluation using the AxSYM system. Urology 1997; 49: 19-27.
18. Lauderer A, Chen YT, Soriano TF, et al. Measurement of the proportion of free to total prostate specific antigen improves diagnostic performance of prostate specific antigen in the diagnostic gray zone of total prostate specific antigen. Urology 1995; 46: 187-94.
19. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998; 279: 1542-7.
20. Price CP, Allard J, Davies G, et al. Pre and post analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. Ann Clin Biochem 2001; 38: 188-216.
21. Brawer MK, Duam P, Petteway JC, Wener MH. Assay variability in serum prostate specific antigen determination. Prostate 1995; 26: 1-6.